BIO International 2026

🇺🇸 🇫🇷Meet Lys Therapeutics at BIO2026 in San Diego!

Dr. Manuel Blanc, Co-founder & CEO, and Philippe Dujardin, Co-founder & CFO, will represent Lys Therapeutics at the BIO International Convention 2026, from June 22 to 25.

We look forward to connecting with biotech, pharma, investor, and strategic partners as we advance LYS241, our first-in-class antibody targeting the tPA-NMDAr pathway.

LYS241 is a late preclinical-stage asset currently progressing through IND/CTA-enabling studies, designed to address blood-brain barrier dysfunction, neuroinflammation, and neurovascular injury through a differentiated vascular approach to severe CNS diseases, with potential across ParkinsonsDisease, MSA, Stroke, and beyond.

Reach out to connect with our team in San Diego.

See you at BIO2026!